VSTM: Pivotal G12D inhibitor data and commercial momentum drive expansion and strategic partnerships
Key updates include strong progress in the G12D inhibitor program with pivotal data expected in October, robust commercial growth for avutometinib/defactinib, and strategic plans for phase III trials and partnerships. The G12D inhibitor is positioned as best-in-class with high efficacy and safety.B…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.